Hamilton, Betty K. http://orcid.org/0000-0003-1252-6539
Williams, Paul http://orcid.org/0000-0001-6259-0390
Galvin, John http://orcid.org/0000-0001-8722-0230
Turnbull, James
Yu, Jingbo http://orcid.org/0000-0001-9819-0735
Funding for this research was provided by:
Incyte Corporation
Article History
Received: 29 April 2024
Accepted: 12 June 2024
First Online: 25 June 2024
Declarations
:
: Betty K. Hamilton has served on an advisory board for Sanofi, Rigel, NKARTA, and Maat, and has received consultancy fees from the ACI Group and Incyte and webinar fees from Therakos, and served on the data safety monitoring board for Angiocrine and the adjudication committee for CSL Behring. Paul Williams and James Turnbull are employees of IQVIA, the company commissioned by Incyte Corporation to conduct this study. John Galvin and Jingbo Yu are employees and shareholders of Incyte. Incyte was involved in the design of the study and data collection. Authors employed at Incyte participated in the analysis and interpretation of data as well as writing the manuscript. Other Incyte employees reviewed the manuscript and provided comments.
: The study was conducted in accordance with the ethical principles embodied by the Declaration of Helsinki and Good Clinical Practice. The survey, including revisions based on a pilot survey with three participants, was reviewed and approved by the New England Institutional Review Board before implementation. All respondents provided informed consent via an online consent form before initiation of the survey. All study participants from the initial study consented to their data being used for further research purposes.